Modjarrad, K., Lin, L., George, S. L., Stephenson, K. E., Eckels, K. H., De La Barrera, R. A., Jarman, R. G., Sondergaard, E., Tennant, J., Ansel, J. L., Mills, K., Koren, M., Robb, M. L., Barrett, J., Thompson, J., Kosel, A. E., Dawson, P., Hale, A., Tan, C. S., Walsh, S. R., Meyer, K. E., Brien, J., Crowell, T. A., Blazevic, A., Mosby, K., Larocca, R. A., Abbink, P., Boyd, M., Bricault, C. A., Seaman, M. S., Basil, A., Walsh, M., Tonwe, V., Hoft, D. F., Thomas, S. J., Barouch, D. H., & Michael, N. L. (2018). preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet, 391(10120), 563–571. http://access.bl.uk/ark:/81055/vdc_100056817529.0x00004c